DRG Market Assessment reports

MARKET OUTLOOK Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. SLE symptoms range from general malaise to serious CNS and renal…

The primary goal of glaucoma treatment is to reduce and control intraocular pressure. In the United States, the treatment armamentarium for open-angle glaucoma (OAG) has expanded in recent years…

The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval of hormonal agents such as Zytiga (Johnson & Johnson), Xtandi (…

2020 will be a turning point for the U.S. acute migraine market. Three novel therapies—Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and Biohaven’s Nurtec ODT—entered the market in rapid…

Tumor necrosis factor-alpha (TNF-α) inhibitors (e.g., AbbVie’s Humira, Amgen’s Enbrel) and Janssen’s interleukin (IL)-12/23 inhibitor Stelara have been leading the U.S. psoriasis biologics…

The poly ADP ribose polymerase (PARP) inhibitors, such as AstraZeneca’s Lynparza, GSK’s Zejula, and Clovis Oncology’s Rubraca, have revolutionized the therapeutic landscape of platinum-…

Since the approval of the first biosimilar in Europe more than a decade ago, the adoption of biosimilars has been increasing among all specialties. The FDA approved Sandoz’s Zarxio (filgrastim)…

Biosimilars of erythropoiesis-stimulating agents (ESAs) entered the European market a decade ago, but the FDA did not approve the first ESA biosimilar—Retacrit—until June 2018; it launched in…

Primary, or essential, hypertension is defined as persistently elevated blood pressure without any identifiable cause. It is a major risk factor for various cardiovascular diseases (e.g., coronary…

–

Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud…

Multiple treatment options—topical therapies, oral drugs, phototherapy, and biologics—are available to treat psoriasis. In particular, the approval of biologics other than TNF-α inhibitors (…